Company Overview and News

 
GLOBAL BIOENERGIES: 2017 FINANCIAL RESULTS

2018-04-18 globenewswire
Net loss for the Group of €14.25m in 2017, including a €2.2m amortisation of the demo plant, i.e. a burn rate of around €12m
Upvote Downvote

 
GLOBAL BIOENERGIES : RESULTATS ANNUELS AU 31 DECEMBRE 2017

2018-04-18 globenewswire
Perte nette du Groupe de 14,25 M€ sur l'exercice 2017, dont 2,2 M€ d'amortissement du démonstrateur, soit un burn rate d'environ 12 M€
Upvote Downvote

 
GLOBAL BIOENERGIES: JAHRESABSCHLUSS PER 31. DEZEMBER 2017

2018-04-18 globenewswire
Konzernverlust von 14,25 Mio. Euro im Jahr 2017, davon 2,2 Mio. Euro Abschreibung für die Demonstrationsanlage, was einer Cash-Burn Rate von rund 12 Mio. Euro entspricht.
Upvote Downvote

 
GLOBAL BIOENERGIES und SkyNRG kündigen Kooperation bei der ASTM-Zertifizierung eines auf Isobuten basierenden Umwandlungsprozesses für die Herstellung nachhaltigen Flugbenzins an

2018-04-17 globenewswire
Global Bioenergies und SkyNRG kündigen Kooperation bei der ASTM-Zertifizierung eines auf Isobuten basierenden Umwandlungsprozesses für die Herstellung nachhaltigen Flugbenzins an
Upvote Downvote

 
GLOBAL BIOENERGIES et SkyNRG annoncent leur collaboration sur la certification ASTM du bio-isobutène et de sa conversion en biocarburant aéronautique durable

2018-04-17 globenewswire
Global Bioenergies et SkyNRG annoncent leur collaboration sur la certification ASTM du bio-isobutène et de sa conversion en biocarburant aéronautique durable
Upvote Downvote

 
GLOBAL BIOENERGIES and SkyNRG announce their collaboration on ASTM-certification of a bio-isobutene feedstock and conversion process for the production of sustainable aviation fuel

2018-04-17 globenewswire
Global Bioenergies and SkyNRG announce their collaboration on ASTM-certification of a bio-isobutene feedstock and conversion process for the production of sustainable aviation fuel
Upvote Downvote

 
Audi Joins French Quest for Biofuels That Won't Challenge Food - Bloomberg

2018-04-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
NEW VIDEO BY GLOBAL BIOENERGIES: FIRST CAR DRIVING WITH GLOBAL BIOENERGIES' RENEWABLE GASOLINE

2018-04-11 globenewswire
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performance of its process, to operate its demo plant in Germany, and to prepare the first full-scale plant through a joint venture with Cristal Union, named IBN-One.
Upvote Downvote

 
GLOBAL BIOENERGIES : Global Bioenergies to present at the Microcap investors conference in New-York, on the 10th of April 2018

2018-04-06 globenewswire
Global Bioenergies to present at the Microcap investors conference in New-York, on the 10th of April 2018
Upvote Downvote

 
GLOBAL BIOENERGIES : Erstes Auto fährt mit dem erneuerbaren Benzin von Global Bioenergies

2018-04-05 globenewswire
Evry (Frankreich) - 05. April 2018 - Heute wird Global Bioenergies zum ersten Mal eine EN228-konforme Benzinmischung verwenden, die über 34 % erneuerbare, isobutenabgeleitete Verbindungen enthält, um ein Auto auf einer Rennstrecke zu betreiben. Global Bioenergies wird auch die Ergebnisse der in den letzten Monaten von der FEV, einem europäischen Marktführer im Bereich Motorenprüfung, durchgeführten Vorversuche vorstellen.
Upvote Downvote

 
GLOBAL BIOENERGIES : Global Bioenergies : premier tour de piste avec de l'essence renouvelable

2018-04-05 globenewswire
Une Audi alimentée à plus de 34 % par de l'essence renouvelable va rouler sur le circuit de Montlhéry
Upvote Downvote

 
GLOBAL BIOENERGIES : First car driving with Global Bioenergies' renewable gasoline

2018-04-05 globenewswire
Evry (France) - 05 April, 2018 - Today, for the first time, Global Bioenergies will use an EN228-compliant gasoline blend containing over 34% of renewable, isobutene-derived, compounds to fuel a car on a circuit. Global Bioenergies will also present the results of preliminary engine testing conducted these past months by FEV, a European leader in engine-testing.
Upvote Downvote

 
GLOBAL BIOENERGIES: Global Bioenergies kündigt die Bekanntgabe von Motortestergebnissen mit erneuerbarem Treibstoff an

2018-03-22 globenewswire
Evry (Frankreich) - 22. März 2018 - Global Bioenergies (Euronext Growth: ALGBE) wird am 5. April Motortestergebnisse präsentieren. Bei der Präsentation werden auch Audi als kommerzieller Partner sowie der deutsche Maschinen- und Treibstoffspezialist FEV zugegen sein.
Upvote Downvote

 
GLOBAL BIOENERGIES : Global Bioenergies va présenter les résultats d'essais moteur réalisés avec ses carburants renouvelables

2018-03-22 globenewswire
Évry - 22 mars 2018 - Global Bioenergies (Euronext Growth : ALGBE) présentera les résultats d'essais moteur le 5 avril prochain en compagnie de son partenaire commercial Audi et de FEV, un groupe allemand spécialisé en motorisation et carburants.
Upvote Downvote

 
GLOBAL BIOENERGIES: Global Bioenergies to present results of engine testing with renewable fuels

2018-03-22 globenewswire
Evry (France) -March 22nd, 2018 - Global Bioenergies (Euronext Growth: ALGBE) will present engine testing results on April 5th. Its commercial partner Audi, and German engine & fuels specialist FEV, will join the presentation.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...